GSA Capital Partners LLP Invests $1.23 Million in Veracyte, Inc. (NASDAQ:VCYT)

GSA Capital Partners LLP bought a new position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 41,432 shares of the biotechnology company's stock, valued at approximately $1,228,000. GSA Capital Partners LLP owned about 0.05% of Veracyte at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc boosted its stake in shares of Veracyte by 1,267.6% in the first quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock valued at $28,000 after buying an additional 862 shares during the period. GF Fund Management CO. LTD. acquired a new position in Veracyte in the 4th quarter valued at approximately $64,000. Sterling Capital Management LLC raised its position in Veracyte by 810.2% during the 4th quarter. Sterling Capital Management LLC now owns 2,421 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 2,155 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Veracyte in the fourth quarter valued at about $152,000. Finally, Neo Ivy Capital Management bought a new position in Veracyte during the 1st quarter worth approximately $173,000.

Veracyte Stock Up 2.0%

NASDAQ:VCYT traded up $0.47 on Monday, hitting $24.11. The stock had a trading volume of 305,650 shares, compared to its average volume of 1,128,658. The business's 50-day simple moving average is $26.23 and its two-hundred day simple moving average is $31.47. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of 58.75 and a beta of 1.97. Veracyte, Inc. has a 52-week low of $19.73 and a 52-week high of $47.32.

Analyst Upgrades and Downgrades

VCYT has been the subject of several recent analyst reports. Guggenheim reduced their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. UBS Group dropped their price objective on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wall Street Zen raised shares of Veracyte from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Needham & Company LLC cut their price target on Veracyte from $51.00 to $41.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Veracyte presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.90.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.